(i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
---|---|---|---|---|---|---|
Yes | No | |||||
Total |
Calendar year (or fiscal year beginning in) | (a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
---|---|---|---|---|---|---|---|
1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | ||||||
2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
4 | Total. Add lines 1 through 3 | ||||||
5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
6 | Public support. Subtract line 5 from line 4. |
Calendar year (or fiscal year beginning in) | (a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
---|---|---|---|---|---|---|---|
7 | Amounts from line 4.. | ||||||
8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
11 | Total support. Add lines 7 through 10 |
Calendar year (or fiscal year beginning in) | (a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
---|---|---|---|---|---|---|---|
1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
6 | Total. Add lines 1 through 5 | ||||||
7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
c | Add lines 7a and 7b.. | ||||||
8 | Public support. (Subtract line 7c from line 6.) |
Calendar year (or fiscal year beginning in) | (a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
---|---|---|---|---|---|---|---|
9 | Amounts from line 6... | ||||||
10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
c | Add lines 10a and 10b. | ||||||
11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
13 | Total support. (Add lines 9, 10c, 11, and 12.).. |
Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
1 | Net short-term capital gain | 1 | ||||
2 | Recoveries of prior-year distributions | 2 | ||||
3 | Other gross income (see instructions) | 3 | ||||
4 | Add lines 1 through 3 | 4 | ||||
5 | Depreciation and depletion | 5 | ||||
6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
7 | Other expenses (see instructions) | 7 | ||||
8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 |
Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
a | Average monthly value of securities | 1a | ||||
b | Average monthly cash balances | 1b | ||||
c | Fair market value of other non-exempt-use assets | 1c | ||||
d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
3 | Subtract line 2 from line 1d | 3 | ||||
4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
6 | Multiply line 5 by .035 | 6 | ||||
7 | Recoveries of prior-year distributions | 7 | ||||
8 | Minimum Asset Amount (add line 7 to line 6) | 8 |
Section C - Distributable Amount | Current Year | |||||
1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
2 | Enter 85% of line 1 | 2 | ||||
3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
4 | Enter greater of line 2 or line 3 | 4 | ||||
5 | Income tax imposed in prior year | 5 | ||||
6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 |
Section D - Distributions | Current Year | |
---|---|---|
1 Amounts paid to supported organizations to accomplish exempt purposes | ||
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
4 Amounts paid to acquire exempt-use assets | ||
5 Qualified set-aside amounts (prior IRS approval required) | ||
6 Other distributions (describe in Part VI). See instructions | ||
7Total annual distributions. Add lines 1 through 6. | ||
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
9 Distributable amount for 2019 from Section C, line 6 | ||
10 Line 8 amount divided by Line 9 amount |
Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2019 |
(iii) Distributable Amount for 2019 |
|
---|---|---|---|---|
1 Distributable amount for 2019 from Section C, line 6 | ||||
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
3 Excess distributions carryover, if any, to 2019: | ||||
a From 2014....... | ||||
b From 2015....... | ||||
c From 2016....... | ||||
d From 2017....... | ||||
e From 2018....... | ||||
fTotal of lines 3a through e | ||||
g Applied to underdistributions of prior years | ||||
h Applied to 2019 distributable amount | ||||
i
Carryover from 2014 not applied (see instructions) |
||||
j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
4Distributions for 2019 from Section D, line 7: | ||||
$ | ||||
a Applied to underdistributions of prior years | ||||
b Applied to 2019 distributable amount | ||||
c Remainder. Subtract lines 4a and 4b from 4. | ||||
5
Remaining underdistributions for years prior to 2019, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
6
Remaining underdistributions for 2019. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
7 Excess distributions carryover to 2020. Add lines 3j and 4c. |
||||
8 Breakdown of line 7: | ||||
a Excess from 2015..... | ||||
b Excess from 2016..... | ||||
c Excess from 2017..... | ||||
d Excess from 2018..... | ||||
e Excess from 2019..... |
Facts And Circumstances Test |
---|
Return Reference | Explanation |
---|---|
PART I, LINE 4 | IN 2019, STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") SCIENTISTS COLLABORATED WITH RESEARCHERS AT 70 NATIONAL AND 50 INTERNATIONAL INSTITUTIONS INCLUDING DOZENS OF HOSPITALS, MEDICAL CENTERS, AND MEDICAL SCHOOLS. MANY OF THESE COLLABORATIONS RESULTED IN DISCOVERIES THAT MERITED PUBLICATION IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS AND/OR SUCCESSFULLY FUNDED GRANT AWARDS. SIMR CONDUCTS MEDICAL RESEARCH IN CONJUNCTION WITH THE UNIVERSITY OF KANSAS (KU) AND ITS AFFILIATES THE UNIVERSITY OF KANSAS HOSPITAL AUTHORITY AND THE UNIVERSITY OF KANSAS MEDICAL CENTER (KUMC), PURSUANT TO A WRITTEN MEMORANDUM OF UNDERSTANDING. KUMC IS THE ACADEMIC HEALTH SCIENCE CENTER OF THE LARGEST PUBLIC RESEARCH UNIVERSITY IN THE STATE OF KANSAS. KUMC OFFERS PROGRAMS AND SERVICES THAT FOCUS ON EDUCATION, RESEARCH, PATIENT CARE, AND COMMUNITY ENGAGEMENT. AS OF DECEMBER 31, 2019, FIVE KUMC STUDENTS HAVE RECEIVED MS DEGREES AND 45 KUMC STUDENTS HAVE RECEIVED PHD DEGREES FOR THESIS WORK PERFORMED IN SIMR'S LABS. KUMC IS AFFILIATED WITH THE UNIVERSITY OF KANSAS HOSPITAL, A NONPROFIT INDEPENDENT HOSPITAL CO-LOCATED WITH THE MAIN KUMC CAMPUS IN KANSAS CITY, KS. IN 2019, TWENTY SIMR RESEARCH PROGRAM LEADERS WERE ADJUNCT FACULTY IN FOUR KUMC DEPARTMENTS. THESE APPOINTMENTS INCLUDED 12 FULL PROFESSORS, FOUR ASSOCIATE PROFESSORS, AND FOUR ASSISTANT PROFESSORS. IN 2019, 52 OF SIMR'S 74 ORIGINAL RESEARCH PUBLICATIONS INCLUDED BOTH SIMR AND KUMC AFFILIATIONS. ABOUT A DOZEN KUMC STUDENTS PERFORMED PREDOCTORAL RESEARCH IN SIMR LABS IN 2019. SIMR IS ALSO A CONSORTIUM MEMBER OF THE UNIVERSITY OF KANSAS CANCER CENTER AT KUMC, A CANCER RESEARCH AND CARE PARTNERSHIP SPANNING TWO STATES AND INVOLVING COLLABORATION AMONG RESEARCHERS, PHYSICIANS, AND CANCER SUPPORT PROFESSIONALS IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH AREAS. IN JUNE 2012, THE NIH'S NATIONAL CANCER INSTITUTE (NCI) NAMED THE UNIVERSITY OF KANSAS CANCER CENTER A NCI-DESIGNATED CANCER CENTER. THE NCI CANCER CENTERS PROGRAM IS A PILLAR OF FEDERAL CANCER RESEARCH EFFORTS AND INTEGRAL TO THE NCI'S PROGRAMS FOR STUDYING, TREATING, AND PREVENTING CANCER. IN KUMC'S APPLICATION TO THE NCI CANCER CENTERS PROGRAM, $4 MILLION OF THE $48 MILLION IN GRANTS CITED IN THE APPLICATION WERE GRANTS THAT HAD BEEN AWARDED TO SIMR INVESTIGATORS. IN 2019, 12 SIMR RESEARCH PROGRAM LEADERS WERE MEMBERS OF THE UNIVERSITY OF KANSAS CANCER CENTER'S CANCER BIOLOGY RESEARCH PROGRAM, INCLUDING LINHENG LI, PHD, WHO SERVES AS CO-LEADER OF THE PROGRAM. IN 2019, SIMR RESEARCH PROGRAM LEADER MICHAEL WASHBURN, PHD, CONTINUED A RESEARCH PROJECT IN COLLABORATION WITH ROY JENSEN, MD, DIRECTOR OF THE UNIVERSITY OF KANSAS CANCER CENTER. THE OVERALL AIM OF THIS RESEARCH EFFORT IS TO DETERMINE HOW CANCER THERAPEUTICS ACT ON PROTEIN NETWORKS IN CELLS AND TISSUES. DR. JENSEN IS A WORLD-RENOWNED EXPERT ON BREAST CANCER AND HOLDS ADDITIONAL POSITIONS AS DIRECTOR, KANSAS MASONIC CANCER RESEARCH INSTITUTE, WILLIAM R. JEWELL DISTINGUISHED KANSAS MASONIC PROFESSOR, AND PROFESSOR OF PATHOLOGY AND LABORATORY MEDICINE, ANATOMY AND CELL BIOLOGY, CANCER BIOLOGY, AND MOLECULAR BIOSCIENCES AT KUMC. THE PROJECT AIMS TO FURTHER EXPLORE THE MECHANISM OF ACTION OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), WHICH IS USED AS CHEMOTHERAPY FOR CERTAIN LYMPHOMAS AND IS BEING EVALUATED IN CLINICAL TRIALS FOR OTHER CANCERS. RECENT REPORTS SUGGEST THAT SAHA HAS ADDITIONAL EFFECTS THAT INVOLVE PROTEIN NETWORKS MORE BROADLY, THUS SUGGESTING OTHER POSSIBLE MECHANISMS OF ACTION. RESULTS FROM THIS JOINT RESEARCH EFFORT MAY ENABLE THE FUTURE DEVELOPMENT OF MORE SPECIFIC AND EFFECTIVE HUMAN THERAPEUTICS. THIS PROJECT IS SUPPORTED IN PART BY A NIH GRANT FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES. IN 2019, SIMR RESEARCH PROGRAM LEADER LINHENG LI, PHD, CONTINUED A COLLABORATION WITH THE UNIVERSITY OF KANSAS CANCER CENTER AND CHILDREN'S MERCY HOSPITAL, KANSAS CITY, MO, TO INVESTIGATE APPROACHES TO TREAT LEUKEMIA. THIS RESEARCH FOCUSES ON TARGETING CANCER STEM CELLS TO HELP REDUCE THE RECURRENCE OF CANCER AFTER A PATIENT GOES INTO REMISSION. THE COLLABORATION BUILDS ON FOUNDATIONAL RESEARCH FROM THE LI LAB THAT HAS CHARACTERIZED CANCER STEM CELLS AT MOLECULAR AND CELLULAR LEVELS. THIS ONGOING RESEARCH COLLABORATION HAS GENERATED FINDINGS THAT HAVE BEEN REPORTED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING ZHAO M ET AL, 2019. KUMC IS THE SPONSOR OF A RELATED CLINICAL RESEARCH STUDY, "LOW-DOSE DAUNORUBICIN IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA," WHICH IS DESIGNED TO ASSESS THE FEASIBILITY AND TOLERABILITY OF ADMINISTERING A LOW DOSE OF THE DRUG TO PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), AND TO OBTAIN PRELIMINARY DATA ON THE DRUG ENGAGING ITS TARGET. SIMR PARTICIPATED IN COLLABORATIONS CONDUCTING RESEARCH IN CONJUNCTION WITH THE FOLLOWING US HOSPITALS, PURSUANT TO AN UNDERSTANDING TO MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH IN 2019: INSTITUTION LOCATION BRIGHAM AND WOMEN'S HOSPITAL BOSTON, MA CHILDREN'S HOSPITAL OF PHILADELPHIA PHILADELPHIA, PA CHILDREN'S MERCY HOSPITAL KANSAS CITY, MO CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER CINCINNATI, OH DANA-FARBER CANCER INSTITUTE BOSTON, MA FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE, WA GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES WASHINGTON, DC GREATER BALTIMORE MEDICAL CENTER TOWSON, MD HARVARD MEDICAL SCHOOL BOSTON, MA JOHNS HOPKINS SCHOOL OF MEDICINE BALTIMORE, MD NEW YORK UNIVERSITY SCHOOL OF MEDICINE NEW YORK, NY NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE CHICAGO, IL OREGON HEALTH AND SCIENCE UNIVERSITY SCHOOL OF MEDICINE PORTLAND, OR PERLMUTTER CANCER CENTER NEW YORK, NY SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE ST LOUIS, MO SEATTLE CHILDREN'S HOSPITAL SEATTLE, WA SINAI HOSPITAL OF BALTIMORE BALTIMORE, MD STANFORD UNIVERSITY SCHOOL OF MEDICINE PALO ALTO, CA UNIVERSITY OF CALIFORNIA LOS ANGELES DAVID GEFFEN SCHOOL OF MEDICINE LOS ANGELES, CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO, CA UNIVERSITY OF KANSAS CANCER CENTER KANSAS CITY, KS UNIVERSITY OF KANSAS MEDICAL CENTER KANSAS CITY, KS UNIVERSITY OF PENNSYLVANIA PERELMAN SCHOOL OF MEDICINE PHILADELPHIA, PA UNIVERSITY OF PITTSBURGH CANCER INSTITUTE PITTSBURGH, PA UNIVERSITY OF ROCHESTER MEDICAL CENTER ROCHESTER, NY UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE COLUMBIA, SC UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER MEMPHIS, TN UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON, TX WEILL CORNELL MEDICINE NEW YORK, NY TO CARRY OUT THE RESEARCH DESCRIBED IN THE FOLLOWING EXAMPLES, SIMR AND HOSPITAL, MEDICAL CENTER, OR MEDICAL SCHOOL ENTERED INTO A COOPERATION AGREEMENT PURSUANT TO WHICH THEY AGREED TO ESTABLISH, DEVELOP, ADMINISTER, AND MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH, INCLUDING THROUGH SPECIFIC COOPERATIVE EFFORTS IN THE AREAS OF RESEARCH, SHARING OF INFORMATION, PURSUANT OF JOINT GRANTS, INTERACTION OF STAFF, ADJUNCT/JOINT APPOINTMENTS, AND SHARING OF FACILITIES. IN ORDER TO ASSURE THE SUCCESS OF THEIR COOPERATIVE RELATIONSHIP, EACH AGREED TO ENGAGE IN EFFECTIVE, COORDINATED AND ONGOING PLANNING, OVERSIGHT, AND COMMUNICATION, AND TO COMMIT THE NECESSARY RESOURCES, BOTH HUMAN AND MONETARY, TO SUPPORT, FACILITATE, AND PROMOTE THE COOPERATION. |
JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS - | THE LI LAB PERFORMED JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS WITH COLLABORATORS AT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA, OREGON HEALTH AND SCIENCE UNIVERSITY SCHOOL OF MEDICINE, STANFORD UNIVERSITY SCHOOL OF MEDICINE, AND UNIVERSITY OF PITTSBURGH CANCER INSTITUTE. INTESTINAL DISEASES RANGING FROM CROHN'S DISEASE TO COLITIS TO CANCER MAY BENEFIT FROM INTESTINAL STEM CELL THERAPIES. THIS RESEARCH ADVANCES THE UNDERSTANDING OF THE BIOLOGY OF STEM CELLS THAT RESIDE IN THE INTESTINE AND EXPLORES HOW THEY CAN BE USED TO TREAT AND CURE INTESTINAL DISEASES. THIS ONGOING RESEARCH COLLABORATION IS SUPPORTED IN PART BY A NIH GRANT AWARDED BY THE NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES. JOINT MEDICAL RESEARCH ON EYE DEVELOPMENT AND FUNCTION - THE XIE LAB PERFORMED JOINT MEDICAL RESEARCH ON GENETIC PROGRAMS THAT REGULATE THE MAMMALIAN EYE WITH COLLABORATORS AT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF ROCHESTER MEDICAL CENTER, AND KYOTO UNIVERSITY. AN EYE STRUCTURE CALLED THE CILIARY BODY IS IMPORTANT FOR CHANGING THE SHAPE OF THE LENS AND FOR PRODUCTION OF THE AQUEOUS HUMOR, THE FLUID THAT MAINTAINS PRESSURE IN THE EYE. DEFECTS IN LENS ACCOMMODATION LEAD TO MYOPIA OR NEARSIGHTEDNESS, WHILE HIGH PRESSURE WITHIN THE EYE IS ONE OF THE MOST IMPORTANT RISK FACTORS FOR GLAUCOMA, THE SECOND LEADING BLIND-CAUSING DISEASE. THE GOAL OF THIS RESEARCH IS TO REVEAL THE MECHANISMS REGULATING THE DEVELOPMENT AND SECRETION OF THE CILIARY BODY. KNOWLEDGE GAINED FROM THESE STUDIES MAY ENHANCE TREATMENTS FOR GLAUCOMA AND MYOPIA. THIS RESEARCH IS SUPPORTED IN PART BY A NIH GRANT FROM THE NATIONAL EYE INSTITUTE. OTHER US COLLABORATORS INCLUDED BERNICE PAUAHI BISHOP MUSEUM, BOSTON COLLEGE, CALIFORNIA INSTITUTE OF TECHNOLOGY, COLD SPRING HARBOR LABORATORY, CORNELIA DE LANGE SYNDROME FOUNDATION, ELMHURST COLLEGE, FLORIDA ATLANTIC UNIVERSITY, HOWARD HUGHES MEDICAL INSTITUTE, INDIANA UNIVERSITY, JOHNS HOPKINS UNIVERSITY, LAWRENCE BERKELEY LABORATORY, MARQUETTE UNIVERSITY, MILLERSVILLE UNIVERSITY, MORGRIDGE INSTITUTE FOR RESEARCH, NATIONAL CANCER INSTITUTE OF THE NATIONAL INSTITUTES OF HEALTH, NATURAL HISTORY MUSEUM OF LOS ANGELES COUNTY, NEW YORK STATE DEPARTMENT OF HEALTH, NEW YORK UNIVERSITY, OPEN UNIVERSITY, PRINCETON UNIVERSITY, PURDUE UNIVERSITY, RUTGERS UNIVERSITY, SOUTHEASTERN LOUISIANA UNIVERSITY, UNIVERSITY OF CALIFORNIA DAVIS, UNIVERSITY OF CALIFORNIA IRVINE, UNIVERSITY OF CALIFORNIA MERCED, UNIVERSITY OF CALIFORNIA SAN DIEGO, UNIVERSITY OF FLORIDA ST AUGUSTINE, UNIVERSITY OF FLORIDA GAINESVILLE, UNIVERSITY OF KANSAS, UNIVERSITY OF KENTUCKY, UNIVERSITY OF MARYLAND, UNIVERSITY OF MINNESOTA, UNIVERSITY OF MISSOURI-KANSAS CITY, UNIVERSITY OF PITTSBURGH, UNIVERSITY OF TEXAS AT ARLINGTON, UNIVERSITY OF VIRGINIA, UNIVERSITY OF WASHINGTON, UNIVERSITY OF WISCONSIN-MADISON, VIRGINIA COMMONWEALTH UNIVERSITY, AND WASHINGTON UNIVERSITY IN ST LOUIS. SIMR COLLABORATED WITH THE FOLLOWING INTERNATIONAL HOSPITALS, MEDICAL CENTERS, AND MEDICAL SCHOOLS IN 2019: BEIJING PERFECT FAMILY HOSPITAL, CHINA; CHINESE ACADEMY OF MEDICAL SCIENCES, TIANJIN, CHINA; HENAN PROVINCIAL PEOPLE'S HOSPITAL, ZHENGZHOU, CHINA; HONG KONG BAPTIST UNIVERSITY, CHINA; HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, CHINA; PEKING UNION MEDICAL COLLEGE, TIANJIN, CHINA; THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSITY, GUANGZHOU, CHINA; TIANJIN MEDICAL UNIVERSITY, HEPING, CHINA; TSINGHUA UNIVERSITY SCHOOL OF MEDICINE,BEIJING, CHINA; WUHAN NO.1 HOSPITAL, HUBEI, CHINA; AND ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE, HANGZHOU, CHINA. OTHER INTERNATIONAL COLLABORATORS INCLUDED AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, SINGAPORE; BARCELONA INSTITUTE OF SCIENCE AND TECHNOLOGY, SPAIN; CARDIFF UNIVERSITY, CATHAYS, UNITED KINGDOM; CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA, MADRID, SPAIN; CIENCIAS BIOLOGICAS, QUITO, ECUADOR; CZECH ACADEMY OF SCIENCES, PRAGUE; DURHAM UNIVERSITY, UNITED KINGDOM; ECOLE POLYTECHNIQUE, PALAISEAU, FRANCE; FRIEDRICH MIESCHER LABORATORY OF THE MAX PLANCK SOCIETY, TUBINGEN, GERMANY; HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA; HUBEI UNIVERSITY, WUHAN, CHINA; INSTITUTO DE FISIOLOGIA, MENDOZA, ARGENTINA; INSTITUTO DE HISTOLOGIA Y EMBRIOLOGIA, MENDOZA, ARGENTINA; INTERNATIONAL IBERIAN NANOTECHNOLOGY LABORATORY, BRAGA, PORTUGAL; ISRAEL INSTITUTE OF TECHNOLOGY, HAIFA; JILIN UNIVERSITY, CHANGCHUN, CHINA; KIEL UNIVERSITY, GERMANY; KYOTO UNIVERSITY, JAPAN; MAX PLANCK INSTITUTE FOR EVOLUTIONARY BIOLOGY, PLON, GERMANY; MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS, DRESDEN, GERMANY; NATIONAL RESEARCH COUNCIL, PISA, ITALY; OSAKA UNIVERSITY, JAPAN; RESEARCH CENTRE FOR MEDICAL GENETICS, MOSCOW, RUSSIA; SEJONG UNIVERSITY, SEOUL, KOREA; SHENZHEN UNIVERSITY, CHINA; SUN YAT-SEN UNIVERSITY, GUANGZHOU, CHINA; TEL AVIV UNIVERSITY, ISRAEL; TOHOKU UNIVERSITY, SENDAI, JAPAN; TSINGHUA UNIVERSITY, BEIJING, CHINA; UNIVERSITY OF HELSINKI, FINLAND; UNIVERSITY OF MILAN, ITALY; UNIVERSITY OF SASKATCHEWAN, SASKATOON, CANADA; UNIVERSITY OF SCIENCE AND TECHNOLOGY, HONG KONG, CHINA; UNIVERSITY OF TOKYO, JAPAN; UNIVERSITY OF TORONTO, CANADA; UNIVERSITY OF WURZBURG, GERMANY; UNIVERSITY OF ZURICH, SWITZERLAND; WELLCOME SANGER INSTITUTE, HINXTON, UNITED KINGDOM; AND YONSEI UNIVERSITY COLLEGE OF DENTISTRY, SEOUL, KOREA. |
Software ID: | |
Software Version: |